Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD

NCT02773797 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

FED

Sponsor class

Conditions

COPD

Interventions

DRUG: IN-DEX 1.0 mcg/kg, intranasal saline
DRUG: IN-DEX 1.5 mcg/kg, intranasal saline
DRUG: Placebo - Saline

Sponsor

Dayton VA Medical Center